MA55750A - Formulations d'anticorps stables et à faible viscosité et leurs utilisations - Google Patents

Formulations d'anticorps stables et à faible viscosité et leurs utilisations

Info

Publication number
MA55750A
MA55750A MA055750A MA55750A MA55750A MA 55750 A MA55750 A MA 55750A MA 055750 A MA055750 A MA 055750A MA 55750 A MA55750 A MA 55750A MA 55750 A MA55750 A MA 55750A
Authority
MA
Morocco
Prior art keywords
stable
low
antibody formulations
viscosity antibody
viscosity
Prior art date
Application number
MA055750A
Other languages
English (en)
Inventor
Manjori Ganguly
Yatin Gokarn
Kelvin Rembert
Atul Saluja
Original Assignee
Sanofi Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=70295163&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA55750(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Sa filed Critical Sanofi Sa
Publication of MA55750A publication Critical patent/MA55750A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
MA055750A 2019-04-23 2020-04-23 Formulations d'anticorps stables et à faible viscosité et leurs utilisations MA55750A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837518P 2019-04-23 2019-04-23
EP20305145 2020-02-17

Publications (1)

Publication Number Publication Date
MA55750A true MA55750A (fr) 2022-03-02

Family

ID=70295163

Family Applications (1)

Application Number Title Priority Date Filing Date
MA055750A MA55750A (fr) 2019-04-23 2020-04-23 Formulations d'anticorps stables et à faible viscosité et leurs utilisations

Country Status (15)

Country Link
US (1) US20220218607A1 (fr)
EP (1) EP3958896A1 (fr)
JP (2) JP7671697B2 (fr)
KR (1) KR20220004104A (fr)
CN (1) CN114286690A (fr)
AU (1) AU2020262231A1 (fr)
BR (1) BR112021021099A2 (fr)
CA (1) CA3137464A1 (fr)
CO (1) CO2021015561A2 (fr)
IL (1) IL287435A (fr)
MA (1) MA55750A (fr)
MX (1) MX2021012968A (fr)
SG (1) SG11202111740PA (fr)
TW (1) TW202108171A (fr)
WO (1) WO2020216847A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11655302B2 (en) 2019-06-10 2023-05-23 Sanofi Anti-CD38 antibodies and formulations
TW202133879A (zh) * 2019-12-05 2021-09-16 美商賽諾菲阿凡提斯美國有限責任公司 用於皮下投予之抗cd38抗體的調配物
US20250145730A1 (en) * 2021-12-16 2025-05-08 Shanghai Bao Pharmaceuticals Co., Ltd. Anti-immunoglobulin degrading enzyme-digested fc variant
WO2024023843A1 (fr) * 2022-07-26 2024-02-01 Dr. Reddy’S Laboratories Limited Formulation pharmaceutique d'un anticorps thérapeutique et ses préparations
WO2026006689A2 (fr) 2024-06-28 2026-01-02 Firefly Bio, Inc. Conjugués anticorps-dégradeur de bcl-xl et leurs utilisations

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5460944A (en) * 1991-10-28 1995-10-24 Boehringer Mannheim Gmbh Storable protein solution
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2672902C (fr) 2006-12-21 2012-11-27 Amgen Inc. Formulations
BRPI0915448A2 (pt) 2008-07-08 2015-11-10 Abbott Lab imunoglobulinas de domínio variável duplo para prostaglandina e2 e usos das mesmas
KR20120060877A (ko) 2009-09-01 2012-06-12 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
TW201119676A (en) 2009-10-15 2011-06-16 Abbott Lab Dual variable domain immunoglobulins and uses thereof
UY32979A (es) 2009-10-28 2011-02-28 Abbott Lab Inmunoglobulinas con dominio variable dual y usos de las mismas
TWI505838B (zh) * 2010-01-20 2015-11-01 中外製藥股份有限公司 Stabilized antibody solution containing
BR112012022223B1 (pt) * 2010-03-01 2022-08-09 Cytodyn Inc Formulação de proteína concentrada, uso e método de preparação da mesma
EP3252072A3 (fr) 2010-08-03 2018-03-14 AbbVie Inc. Immunoglobuline à double domaine variable et ses utilisations
JP6345123B2 (ja) * 2012-02-16 2018-06-20 サンタラス， インコーポレイテッド 抗ｖｌａ１（ｃｄ４９ａ）抗体医薬組成物
SI2922875T1 (sl) * 2012-11-20 2017-06-30 Sanofi Protitelesa anti-CEACAM5 in njihove uporabe
US20160058863A1 (en) * 2014-09-03 2016-03-03 Board Of Regents, The University Of Texas System Low viscosity concentrated protein dispersions
EP3824906A1 (fr) * 2016-12-21 2021-05-26 Amgen Inc. Formulations d'anticorps anti-tnf alpha
EP3559033A1 (fr) * 2016-12-22 2019-10-30 Sanofi Anticorps cxcr3 humanisés ayant une activité de déplétion et leurs procédés d'utilisation

Also Published As

Publication number Publication date
CO2021015561A2 (es) 2021-12-10
BR112021021099A2 (pt) 2021-12-14
TW202108171A (zh) 2021-03-01
EP3958896A1 (fr) 2022-03-02
KR20220004104A (ko) 2022-01-11
JP2025087851A (ja) 2025-06-10
CN114286690A (zh) 2022-04-05
AU2020262231A1 (en) 2021-12-16
US20220218607A1 (en) 2022-07-14
JP7671697B2 (ja) 2025-05-02
CA3137464A1 (fr) 2020-10-29
JP2022530050A (ja) 2022-06-27
WO2020216847A1 (fr) 2020-10-29
MX2021012968A (es) 2022-01-18
IL287435A (en) 2021-12-01
SG11202111740PA (en) 2021-11-29

Similar Documents

Publication Publication Date Title
MA55750A (fr) Formulations d'anticorps stables et à faible viscosité et leurs utilisations
EP3794037A4 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
EP3762031A4 (fr) Anticorps anti-claudine 18.2 et leurs utilisations
EP3980437A4 (fr) Amidites d'una et leurs utilisations
MA52426A (fr) Conjugués d'il-15 et leurs utilisations
EP3924389A4 (fr) Anticorps anti-claudine 6 et leurs utilisations
EP3958910A4 (fr) Conjugués anticorps anti-cd45-médicaments et leurs utilisations
EP3950716A4 (fr) Anticorps anti-claudine 18.2 et utilisation associée
MA49457A (fr) Molécules d'anticorps se liant à cd73 et leurs utilisations
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
MA56517A (fr) Arn messager comprenant des éléments d'arn fonctionnels et leurs utilisations
MA53122A (fr) Variants d'anticorps cd38 et leurs utilisations
EP3876973A4 (fr) Conjugués d'interleukine 10 et leurs utilisations
EP3873940A4 (fr) Anticorps anti-ctla4, fragments d'anticorps, leurs immunoconjugués et utilisations associées
EP3681912A4 (fr) Anticorps spécifiques d'axl et leurs utilisations
MA52626A (fr) Anticorps anti-cd63, conjugués et leurs utilisations
MA56205A (fr) Anticorps anti-pcrv qui se lient à pcrv, compositions comprenant des anticorps anti-pcrv, et leurs méthodes d'utilisation
EP3958861A4 (fr) Dégradeurs de la kinase cycline-dépendante 12 (cdk12) et leurs utilisations
MA55491A (fr) Anticorps anti-pyroglutamate-amyloïde bêta et leurs utilisations
EP4200335A4 (fr) Compositions d'anticorps anti-cd5 et leurs utilisations
MA54148A (fr) Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation
MA50670A (fr) Nouvelles formulations permettant de stabiliser des compositions d'anticorps à faible dose
EP4222174A4 (fr) Anticorps ciblant la claudine 18.2 humaine et leurs utilisations
EP4051711A4 (fr) Anticorps anti-cd45 et leurs conjugués
EP3962954A4 (fr) Anticorps anti-galectine-9 et leurs utilisations